Cargando…
An examination of clinical differences between carriers and non-carriers of chromosome 8q24 risk alleles in a New Zealand Caucasian population with prostate cancer
Background. Prostate cancer makes up approximately 15% of all cancers diagnosed in men in developed nations and approximately 4% of cases in developing nations. Although it is clear that prostate cancer has a genetic component and single nucleotide polymorphisms (SNPs) can contribute to prostate can...
Autores principales: | Bishop, Karen S., Han, Dug Yeo, Karunasinghe, Nishi, Goudie, Megan, Masters, Jonathan G., Ferguson, Lynnette R. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
PeerJ Inc.
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4782686/ https://www.ncbi.nlm.nih.gov/pubmed/26966665 http://dx.doi.org/10.7717/peerj.1731 |
Ejemplares similares
-
A pilot study to investigate if New Zealand men with prostate cancer benefit from a Mediterranean-style diet
por: Erdrich, Sharon, et al.
Publicado: (2015) -
Quality of life effects of androgen deprivation therapy in a prostate cancer cohort in New Zealand: can we minimize effects using a stratification based on the aldo-keto reductase family 1, member C3 rs12529 gene polymorphism?
por: Karunasinghe, Nishi, et al.
Publicado: (2016) -
Interaction between leukocyte aldo-keto reductase 1C3 activity, genotypes, biological, lifestyle and clinical features in a prostate cancer cohort from New Zealand
por: Karunasinghe, Nishi, et al.
Publicado: (2019) -
Selenium, Selenoprotein Genes and Crohn’s Disease in a Case-Control Population from Auckland, New Zealand
por: Gentschew, Liljana, et al.
Publicado: (2012) -
Influence of lifestyle and genetic variants in the aldo-keto reductase 1C3 rs12529 polymorphism in high-risk prostate cancer detection variability assessed between US and New Zealand cohorts
por: Karunasinghe, Nishi, et al.
Publicado: (2018)